Jazz Pharmaceuticals (JAZZ) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a ...

2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of Chimerix, Inc. ("Chimerix") for approximately ...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced the successful completion of its ...

Addition of dordaviprone strengthens Jazz's late-stage oncology pipeline and reinforces commitment to addressing rare diseases with significant unmet need - DUBLIN, April 21, 2025 /PRNewswire/ ...

Jazz Pharmaceuticals has acquired Chimerix Inc. for approximately $935 million in cash. Chimerix is now a wholly owned subsidiary of Jazz.

With Q4 behind us, let’s have a look at Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers. The pharmaceuticals sector is pivotal in the development, manufacturing, and distribution of drugs and ...

Ahead of a planned trial next month, Jazz Pharmaceuticals is moving to resolve antitrust allegations surrounding its key narcolepsy drug Xyrem with a cool $145 million settlement. | The company ...

While JAZZ Pharmaceuticals JAZZ may not be a typical cannabis stock, it is the only company to market an FDA-approved drug that contains a purified drug substance derived from marijuana.

About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families.

April 8 (Reuters) - Jazz Pharmaceuticals (JAZZ.O), opens new tab said on Tuesday that it had agreed to a settlement of $145 million to resolve a series of antitrust lawsuits related to its ...